The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
Open accessAbstract
Purpose: To compare three-drug chemotherapy with cisplatin, doxorubicin, and methotrexate with four-drug chemotherapy with cisplatin, doxorubicin, methotrexate, and ifosfamide for the treatment of osteosarcoma. To determine whether the addition of muramyl tripeptide (MTP) to chemotherapy enhances event-free survival (EFS) and overall survival in newly diagnosed patients with osteosarcoma. Patients and Methods: Six hundred sixty-two patients with osteosarcoma without clinically detectable metastatic disease and whose disease was considered resectable received one of four prospectively randomized treatments. All patients received identical cumulative doses of cisplatin, doxorubicin, and methotrexate and underwent definitive surgical resection of primary tumor. Patients were randomly assigned to receive or not to receive ifosfamide and/or MTP in a 2 × 2 factorial design. The primary end points for analysis were EFS and overall survival. Results: In the current analysis, there was no evidence of interaction, and we were able to examine each intervention separately. The chemotherapy regimens resulted in similar EFS and overall survival. There was a trend toward better EFS with the addition of MTP (P = .08). The addition of MTP to chemotherapy improved 6-year overall survival from 70% to 78% (P = .03). The hazard ratio for overall survival with the addition of MTP was 0.71 (95% CI, 0.52 to 0.96). Conclusion: The addition of ifosfamide to cisplatin, doxorubicin, and methotrexate did not enhance EFS or overall survival for patients with osteosarcoma. The addition of MTP to chemotherapy resulted in a statistically significant improvement in overall survival and a trend toward better EFS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a finding that was reproduced to some extent in humans 67,68 .”
From Osteosarcoma (2022) · cites this paper as [67]
In the citing paper
“There has been a long-standing interest in immune-based therapies centred on the activity of mifamurtide in osteosarcoma in phase II and subsequently on a randomized phase III trial conducted by the Children's Oncology Group 81 .”
From Osteosarcoma (2022) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Principles and Practice of Pediatric Oncology
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-8-636_3 · Cited by 2,034
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,203
Self-citationMeyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D. L., Bernstein, M. L., Conrad, E. U., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.031 · Cited by 717
Self-citationChemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers, P. A., Heller, G., Healey, J. H., Huvos, A. G., Lane, J. M., Marcove, R. C., Applewhite, A., Vlamis, V., & Rosen, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.5 · Cited by 675
Self-citationKempf-Bielack, B., Bielack, S. S., Jürgens, H., Branscheid, D., Berdel, W. E., Exner, G. U., Göbel, U., Helmke, K., Jundt, G., Kabisch, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.063 · Cited by 643
Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery
Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979) · Cancer · doi:10.1002/1097-0142(197906)43:6 · Cited by 584
Interim analysis: The alpha spending function approach
DeMets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 565
Souhami, R. L., Craft, A. W., van der Eijken, J. W., Nooij, M. A., Spooner, D. A., Bramwell, V. H. C., Wierzbicki, R. F., MALCOLM, A. J., Kirkpatrick, A., Uscinska, B., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02307-6 · Cited by 381
Cited by
Sorted by citations
Items 601–700 of 756
Macrophages and pathophysiology of bone cancers
Sousa, S., & Määttä, J. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00009-1 · Cited by 1
Součková, L., Mazánek, P., & Múdrý, P. (2016) · Klinická farmakologie a farmacie · doi:10.36290/far.2016.019 · Cited by 1
Immunological and Genetic Biomarkers of Sarcomas
D’Ambrosio, L., Sangiolo, D., Merlini, A., Grignani, G., & Aglietta, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00042-9 · Cited by 1
Barnett, S., & Cable, M. G. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.87992 · Cited by 1
Osteosarcoma: History of Therapy
Meyers, P. A. (2020) · Pediatric oncology · doi:10.1007/978-3-030-51160-9_7 · Cited by 1
Self-citationHendershot, E. (2010) · Pediatric oncology · doi:10.1007/978-3-540-87984-8_3 · Cited by 1
Systemische Therapie von Osteosarkomen
Bielack, S., Reichardt, P., Lindner, L. H., & Hecker‐Nolting, S. (2022) · Die Onkologie · doi:10.1007/s00761-022-01119-6 · Cited by 1
Jimmy, R., White, S., & Lisy, K. (2014) · The JBI Database of Systematic Reviews and Implementation Reports · doi:10.11124/jbisrir-2014-1774 · Cited by 1
Monárrez‐Espino, J., Romero-Rodríguez, L., Escamilla-Asiaín, G., Ellis‐Irigoyen, A., Cubría‐Juárez, M. D. P., Sematimba, D., Galindo, C. R., & Vega‐Vega, L. (2022) · Cancer Reports · doi:10.1002/cnr2.1702 · Cited by 1
Assessment of Chemotherapy Response and Modification of Chemotherapy in Pediatric Cancer Management
Srinivasan, S., & Kanwar, V. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-71113-9_29-1 · Cited by 1
Malignant Brain and Spinal Tumors Originating from Bone or Cartilage
Gersey, Z. C., Zenonos, G. A., & Gardner, P. A. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-23705-8_18 · Cited by 1
Gupta, N. M., Dimri, K., Garg, S. K., Pandey, A. K., & Arora, A. (2024) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0044-1795133 · Cited by 1
PET image nonuniformity texture features for metastasis risk prediction in osteosarcoma
Almaslamani, M., Byun, B.-H., Song, K., Kong, C., & Woo, S. (2025) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001989 · Cited by 1
Osteosarcoma therapy: what is the way forward?
Andrews, N. A. (2013) · IBMS BoneKEy · doi:10.1038/bonekey.2013.106 · Cited by 1
Clinical trials of systemic therapy in osteosarcoma and Ewing’s sarcoma: past, present and future
Rowe, R. G., & Chugh, R. K. (2011) · Clinical Investigation · doi:10.4155/cli.11.128 · Cited by 1
Introduction: Malignant primary bone tumors in children and young adults
Kent, P. M., Ording, J., Dabrowski, E. C., Shah, K., & Trafton, L. W. (2013) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2013.07.002 · Cited by 1
Royer, B. B.-L., & Blanchard, F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00010-8 · Cited by 1
Is Osteosarcoma between the Two Peak Ages Different?
Kim, T., Chung, H., Cho, W. H., Jeon, D., & Chung, S. H. (2018) · Journal of Cancer Therapy · doi:10.4236/jct.2018.91008 · Cited by 1
Leveraging dogs with spontaneous cancer to advance drug development
Gardner, H. L., Londhe, P., & London, C. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814704-7.00015-5 · Cited by 1
Tsoi, K. M., Samuel, A., Jeys, L. M., Ashford, R. U., & Gregory, J. (2019) · Bone and Joint 360 · doi:10.1302/2048-0105.85.360723 · Cited by 1
Gannon, N. P., McHugh, K. M., Ameduri, R. K., & Ogilvie, C. M. (2021) · JBJS Case Connector · doi:10.2106/jbjs.cc.20.00270 · Cited by 1
The immune environment of bone sarcomas
Richert, I., & Dutour, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821666-8.00070-0 · Cited by 3
Commentary on an article by Kyucheol Noh, MD, et al.
Healey, J. H. (2011) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.k.00007 · Cited by 1
Self-citationTo B(MP-2) or Not To B(MP-2): Cytokines and Tumor Surgery—Response
Weiss, K. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0875 · Cited by 1
Bae, Y., Zeng, H., Lu, L., Wang, L. L., & Lee, B. (2018) · Primer on the metabolic bone diseases and disorders of mineral metabolism · doi:10.1002/9781119266594.ch99 · Cited by 1
Lewis, V. O. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5197-6_28
Puhaindran, M. E., & Athanasian, E. A. (2014) · Springer eBooks · doi:10.1007/978-1-4614-8515-5_63
Ciblage thérapeutique des tumeurs osseuses primitives par transfert de gène
Lamoureux, F. (2008) · OpenGrey (Institut de l'Information Scientifique et Technique)
Pezzani, M., & Moreno, G. (2014) · Medwave · doi:10.5867/medwave.2014.5753
Knochensarkom des Kindes-, Jugend- und jungen Erwachsenenalters
Dirksen, U. (2013) · Der Onkologe · doi:10.1007/s00761-013-2486-0
Le nuove frontiere della ricerca in oncologia del sistema muscolo-scheletrico
Healey, J. H. (2011) · LO SCALPELLO-OTODI Educational · doi:10.1007/s11639-011-0119-1
Self-citationNew Medical/Biologic Paradigms in the Treatment of Bone Tumors
Choong, P. (2014) · Current Surgery Reports · doi:10.1007/s40137-014-0055-0
Future directions for pediatric and young adult bone sarcoma
Finney, J. D., Kent, P. M., & Batus, M. (2013) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2013.07.010
Jones, J. M. (2013) · Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)
Lagmay, J., & Yeager, N. D. (2015) · Pediatric oncology · doi:10.1007/978-3-319-18099-1_14
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma
Basiric, M., Capozzi, F., Soster, M., Fagioli, F., Ferrari, S. M., Alberghini, M., Picci, P., Aglietta, M., & Grignani, G. (2013)
Immunotherapy for Pediatric Solid Tumors
Kopp, L. M., & Katsanis, E. (2015) · Springer eBooks · doi:10.1007/978-3-662-46410-6_3
Malign kemik tümörlerinde kemoterapi
Yalçın, B. (2014) · Türk Ortopedi ve Travmatoloji Birliği Derneği · doi:10.14292/totbid.dergisi.2014.31
The Problem of Cancer in Children
Podda, M. G., Biassoni, V., Meazza, C., Schiavello, E., & Massimino, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-21371-2_11
Taçyıldız, N., Tanyıldız, H. G., Dincaslan, H. U., Yavuz, G., Ünal, E., Özkan, E., Soydal, Ç., Küçük, Ö., & Yıldız, Y. (2016) · Iranian Journal of Pediatrics · doi:10.5812/ijp.4008
Neoadjuvant Chemotherapy: Osaka University Osteosarcoma (OOS) Regimen
Kakunaga, S., Ueda, T., Naka, N., Kuratsu, S., Araki, N., Aoki, Y., & Yoshikawa, H. (2016) · Springer eBooks · doi:10.1007/978-4-431-55696-1_8
Non-surgical Treatment of Pediatric Bone Sarcomas
Sierrasesúmaga, L., Martín, I. R., & Garraus, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-24220-0_2
Neoadjuvant Chemotherapy Developed in Japan
Hiraga, H. (2016) · Springer eBooks · doi:10.1007/978-4-431-55696-1_7
Management of soft tissue and bone tumours in adults
Tilsley, O. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781107280250.035
Osteosarcoma and the use of high-dose chemotherapy
Strauss, S. J., & Shiu, K. (2015) · doi:10.1093/med/9780199688883.003.0017
Knochen- und Weichteilsarkome des Kindes-, Jugend- und jungen Erwachsenenalters
Dirksen, U., Bielack, S., Kościelniak, E., & Klingebiel, T. (2016) · Der Onkologe · doi:10.1007/s00761-016-0133-2
OMICS Approach for Identifying Predictive Biomarkers in Osteosarcoma
Kondo, T. (2017) · InTech eBooks · doi:10.5772/67449
Novel Therapies and Future Directions in Treatment of Musculoskeletal Sarcomas
Khillan, R., Preet, M., DiFrancesco, T., Uzoegwu, U., Ali, O., & Maheshwari, A. V. (2017) · Springer eBooks · doi:10.1007/978-3-319-43121-5_22
Tumors of the Sacrum: The Role of Chemotherapy
Ferrari, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-51202-0_28
Chemotherapy and Other Systemic Approaches to Adult Sarcomas
Priebat, D. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-43121-5_12
IMPROVING NK CELL THERAPY FOR OSTEOSARCOMA
Foltz, J. A. (2017) · Digital Commons-TMC (Texas Medical Center)
Tuohy, J. L. (2017) · NCSU Libraries Repository (North Carolina State University Libraries)
Guenther, L. M., & Janeway, K. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8755-5_40
Reconstructive Surgery after Bone Sarcoma Excision
Ozaki, T. (2018) · リハビリテーション医学 : 日本リハビリテーション医学会誌 · doi:10.2490/jjrmc.55.943
Petca, R., Gavriliu, Ş., & Burnei, G. (2016) · Medicina Moderna - Modern Medicine
Solid Tumors Outside of the Central Nervous System
Schreiber, H. C., & Killinger, J. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-01322-6_4
Davis, E. J., Siegel, G., Feng, M. U.-S., Biermann, J. S., & Chugh, R. K. (2015) · Wiley eBooks · doi:10.1002/9781119013143.ch57
Zhukov, N. V. (2019) · Russian Journal of Pediatric Hematology and Oncology · doi:10.21682/2311-1267-2019-6-1-48-55
Osteosarcoma – on the way to personalized therapy. Part I: standard chemotherapy in the present
Rykov, M. Y., & Рифатовна, С. Э. (2019) · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · doi:10.21508/1027-4065-2019-64-2-47-51
What Is the Best Treatment of Malignant Bone Tumors in Children?
Gupta, A. A., & Hopyan, S. (2009) · Elsevier eBooks · doi:10.1016/b978-141604444-4.50041-2
Osteosarcoma – on the way to personalized therapy. Part II: personalized therapy of the future
Rykov, M. Y., & Рифатовна, С. Э. (2019) · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · doi:10.21508/1027-4065-2019-64-3-28-36
Lewi, D., Peters, K. A., & Politi, P. M. (2014) · doi:10.4155/ebo.13.174
Beltrán, L. M., Eidelman, D. O., & Suárez, N. L. G. (2019) · Universitas Médica · doi:10.11144/javeriana.umed60-4.oste
Dome, J. S., Galindo, C. R., Spunt, S. L., & Santana, V. M. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00095-3
Jung, N., Mayet, W.-J., Mertens, P. R., (federführend), J. M., Müller, O., Pfeifer, R., Schellinger, P. D., Weiss, N., & Wendtner, C. ‐. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50009-7
Sonodynamic and Photodynamic Therapy in Advanced Pancreas Carcinoma - A Case Report
Li, L. Q. (2020) · Online Journal of Complementary & Alternative Medicine · doi:10.33552/ojcam.2019.03.000559
Toward the patient-centred development of cancer therapeutics: A focus on nanomedicines
Freeman, M. W. (2018) · TSpace (University of Toronto)
Late Effects in Children and Adolescents with Osteosarcoma
Bielack, S., Hecker‐Nolting, S., & Beck, J. D. (2020) · Springer eBooks · doi:10.1007/978-3-030-49140-6_30
The Role of Systemic Therapies in the Management of Bone Sarcoma
To, Y. H., Orme, L. M., & Lewin, J. H. (2020) · Springer eBooks · doi:10.1007/978-981-15-9414-4_12
Osteosarkom – Diagnostik, Therapie, Prognose
Tunn, P., Kakkassery, M., & Reichardt, P. (2020) · Der Onkologe · doi:10.1007/s00761-020-00874-8
Assessment and Prevention of Cardiovascular Events in Pediatric Osteosarcoma Survivors
朱, 文. (2020) · Advances in Clinical Medicine · doi:10.12677/acm.2020.1012434
Pediatric Osteosarcoma: Connecting Present and Future Approaches to Diagnosis and Treatment
Kapetanos, K. (2020) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2020.32.005268
Case reports with durable therapeutic effects from the prospective phase 2 trial
Xie, L., Xu, J. H., Sun, X., Tang, X., Sun, K., Li, Y., & Guo, W. (2020) · Medicine Case Reports and Study Protocols · doi:10.1097/md9.0000000000000010
Identification of Metastasis-Related Signature For Predicting Survival In OsteosarcomaPreprint
Shi, S., Yang, S., Zhou, Z., Sun, K., Tao, R., & Wan, F. (2021) · Research Square · doi:10.21203/rs.3.rs-683582/v1
Chemotherapy for Pelvic Bone Tumors
Brunello, A., & Zagonel, V. (2021) · Springer eBooks · doi:10.1007/978-3-030-77007-5_19
Regulated cell death and drug resistance in malignant bone tumors
Richter, G. H. S., Lissat, A., & Kontny, U. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821666-8.00055-4
Şimşek, M., & Ataş, E. (2021) · Current Pediatric Research
Ahrens, M. (2021) · Elsevier eBooks · doi:10.1016/b978-3-437-23824-6.00056-0
The Effect of Ifosfamide and Mifamurtide Loaded Cement on The Viability of Osteosarcoma Cells
Bekçioğlu, Ö., Aktaş, S., Aydın, M., & Olgun, N. (2021) · Turkish Journal of Hip Surgery · doi:10.5505/tjhs.2021.76486
(2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0755-7.00495-4
Faculty Opinions recommendation of Defining trained immunity and its role in health and disease.
Nanchahal, J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737476894.793576526
Kokkali, S., Kotsantis, I., Magou, E., Talagani, S., Kormas, T., Diakoumis, G., Spathas, N., Psyrri, A. K., & Ardavanis, A. S. (2022) · Research Square · doi:10.21203/rs.3.rs-1221515/v1
(2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32832e
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01698-x
Signature based on immune-related LncRNA can predict overall survival of osteosarcoma patientsPreprint
Li, L., Zhang, L., Khader, M. A., Zhang, Y., Lu, X., Zhang, Y., Liu, Y., Wen, J., Liu, T., Yuan, Y., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-45370/v2
Puhaindran, M. E., & Athanasian, E. A. (2014) · Springer eBooks · doi:10.1007/978-1-4614-8758-6_63-1
Kager, L., & Bielack, S. (2017) · Springer eBooks · doi:10.1007/978-3-662-43686-8_29
Matthay, K. K. (2013) · doi:10.1002/9781118625309.ch2
Beckingsale, T., & Ghosh, K. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108686624.025
Bielack, S., Paulussen, M., & Helman, L. J. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198797210.003.0026
BIELACK, S. (2015) · Elsevier eBooks · doi:10.1016/b978-3-437-22061-6.50452-3
Davis, E. J., Siegel, G., Feng, M. U.-S., Biermann, J. S., & Chugh, R. K. (2017) · Wiley eBooks · doi:10.1002/9780471420194.tnmm55
Treatment of children with osteosarcoma
Рифатовна, С. Э., & Rykov, M. Y. (2019) · Yakut Medical Journal · doi:10.25789/ymj.2019.65.29
Tomáš, T., Janíček, P., Pazourek, L., & Mahdal, M. (2017) · Onkologie · doi:10.36290/xon.2017.054
The Effect of Bufalin Combined with Ciplatin on Apoptosis of Osteosarcoma 143B Cells
贾, 林. (2020) · Advances in Clinical Medicine · doi:10.12677/acm.2020.1011407
Metadata
- Authors
- Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., Kleinerman, E., Link, M. P., Nadel, H., Nieder, M., Siegal, G. P., Weiner, M. A., Wells, R. J., Womer, R. B., & Grier, H. E.
- Affiliations
- Children's Oncology Group (US)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2008-02-01
- Volume
- 26
- Issue
- 4
- Pages
- 633-638
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2103405666
- Cited by
- 752
- References
- 20
- Citations by year
- 2026: 21 · 2025: 30 · 2024: 30 · 2023: 31 · 2022: 40 · 2021: 51 · 2020: 70 · 2019: 39 · 2018: 38 · 2017: 55 · 2016: 49 · 2015: 50 · 2014: 57 · 2013: 46 · 2012: 36
- FWCI
- 33.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Children’s Oncology Group
- National Institutes of Health (CA98543)
- National Cancer Institute (U10CA098543, CA-98543)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- osteosarcoma, muramyl tripeptide, ifosfamide, cisplatin, doxorubicin, methotrexate, event-free survival, overall survival, pediatric cancer chemotherapy, immunomodulatory therapy, surgical resection
- MeSH terms
- Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Child, Preschool, Cisplatin, Doxorubicin, Female, Humans, Ifosfamide, Infant, Lung Neoplasms, Male, Methotrexate, Neoplasm Recurrence, Local, Osteosarcoma, Survival Rate, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
